Curaleaf challenges Aurora board’s rejection of its enhanced takeover bid
+1 new source since this summary was written
Curaleaf Holdings publicly contested Aurora Cannabis’ board recommendation to reject its enhanced hostile offer. The company said its proposal carries an 86% premium to Aurora’s 30‑day VWAP and a 217% ex‑cash premium, valuing Aurora at $5.00 per share. Curaleaf accused Aurora of denying due‑diligence access while allowing other parties to review confidential information and questioned the independence of Aurora’s financial advisor.
Why it matters
The dispute signals a prolonged takeover battle that could delay any transaction and affect both companies’ share prices. Aurora’s board stance may depress its stock, while Curaleaf’s criticism could pressure the board to re‑evaluate the offer.
Key facts
- 1Curaleaf’s enhanced proposal represents an 86% premium to Aurora’s unaffected 30‑day volume‑weighted average share price. prnewswire.com
- 2The same proposal represents a 217% premium on an ex‑cash basis. prnewswire.com
- 3Curaleaf values Aurora at $5.00 per share, a 92% premium to Aurora’s July 2026 ATM price of $2.60 per share. rttnews.com
- 4The implied transaction multiple is 14.3× Aurora’s 2026 adjusted EBITDA versus Curaleaf’s 13.7×. benzinga.com
- 5Aurora’s board denied Curaleaf access to due‑diligence data while granting it to other unnamed parties. tradingview.com
- 6Aurora’s shares were up 0.38% at $4.00 and Curaleaf’s were down 1.40% at $7.72 at the time of reporting. benzinga.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.